The day at a glance · 3 min read
Mood · Risk-On
+68
Sentiment, −100 to +100
Moderna Q3 Revenue
$1.3B+29%
Pfizer 2026 Revenue Outlook
$62-64B+$1.5B
Oyster Series A Financing
$60M
Key driverStrong quarterly results from Moderna and raised full-year guidance drove biotech sector strength alongside neurodegenerative disease pipeline advances
Daily briefHealthcare· Money365.Market AI ·

Moderna Surges on Strong Q3; Oyster Raises $60M for Tau

Biotech stocks rally on earnings beats and neurodegenerative disease pipeline funding as Pfizer raises 2026 outlook

Big Pharma & Biotech

Bullish
01MRNA▲ +5.83%
Moderna (MRNA) reported third-quarter 2026 financial results with revenue rising 29% to $1.3 billion and raised its full-year revenue growth forecast. The biotechnology company's shares jumped 6.4% following the results announcement. The revenue growth was largely driven by COVID sales, though those sales have been down significantly over the past five years.
02PFE
Pfizer (PFE) raised its full-year 2026 revenue outlook to $62 billion to $64 billion, representing an increase of $1.5 billion at the midpoint. The pharmaceutical company's shares traded at $29.39 with a 30-day return of 3.92% and a 90-day gain of 10.41%, though the 7-day move was down 4.17%.
03PFE
Pfizer (PFE) also announced licensing activity, with Medicus Pharma (MDCX) outlining its CD228V license from Pfizer alongside a proposed $135 million SkinJet SPAC combination.
04LLY▲ +4.28%
Oyster Therapeutics, formerly Kesmalea Therapeutics, closed a $60 million Series A-2 financing led by 4BIO Capital with participation from new investors including Eli Lilly and Company (LLY). The proceeds will advance an oral, brain-penetrant tau degrader into clinical development as a novel treatment for tau-driven diseases like Alzheimer's. The financing supports continued development of the proprietary SELFTAC platform for generating small bifunctional targeted protein degraders with enhanced drug-like properties.

Clinical Trial Updates

Bullish
AMGNMRK
01
Xenon Pharmaceuticals (XENE) expects pivotal depression study results in December, earlier than previously projected, while preparing for a potential U.S. launch of its lead epilepsy drug. The company is advancing two pain treatments into midstage testing, according to its third-quarter 2026 earnings call.
02AMGN
Amgen (AMGN) announced new data at the American Heart Association Scientific Sessions 2026 showing Repatha cut heart attack risk more than ezetimibe in patients with atherosclerotic cardiovascular disease. The large-scale analysis compared outcomes for high-risk patients treated with Repatha versus ezetimibe in routine clinical practice. Researchers highlighted the findings as potentially relevant for future treatment guidelines for atherosclerotic cardiovascular disease worldwide.
03MRK
Perspective Therapeutics provided updated interim data from Phase 1/2a bamzireotide navoxetan presentations that continue to support an emerging therapeutic window and potential to achieve a best-in-class profile in NETs. The company also reported meaningful antitumor activity for lapemelanotide zapixetar monotherapy in metastatic melanoma, with additional patients to be evaluated. PSV359 received Fast Track Designation from the FDA for FAP-positive solitary fibrous tumors, with an agreement in place with Merck (MRK) to support potential evaluation.

Corporate Governance & M&A

Neutral
UNH
01UNH
UnitedHealth Group (UNH) appointed Madeline Bell, former president and CEO of Children's Hospital of Philadelphia, to its Board of Directors, effective immediately. The appointment adds healthcare delivery expertise to the managed care company's board.
02
Trogenix appointed industry veterans John Young as Chair and Josh Murray as Non-Executive Director to support global strategy, commercial foundation and patient access. John brings more than 35 years of operational and commercial leadership with extensive experience in bringing medicines to market at global scale, while Josh brings deep capital markets and strategic experience to support the company's U.S. expansion, strategic partnerships, commercialisation planning and capital markets readiness. The appointments equip Trogenix for its next phase of growth, scaling its AI-enabled Odysseus cellular precision oncology platform across a broad range of solid tumours.

MedTech & Devices

Neutral

Baillie Gifford Q3 Portfolio

$106B
01ISRG
Intuitive Surgical (ISRG) featured in Zacks research reports highlighting growth drivers, challenges and performance outlooks. The surgical robotics company was included in top research reports alongside other major technology and healthcare names.
02DXCM▲ +2.09%
Dexcom (DXCM) appeared in Baillie Gifford's Q3 2026 13F portfolio, which decreased to approximately $106 billion in total assets. The continuous glucose monitoring device maker remains a holding in the investment firm's healthcare technology allocation.

Important Disclaimer — Not Investment Advice

Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.

Read the full disclaimer — 8 further points, including total-loss risk, our regulatory status and conflicts of interest

Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.

  • You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
  • Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
  • Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
  • Automated content. This brief was compiled by an automated pipeline from validated news and market-data sources and passed through editorial and compliance checks. Automated content can still contain errors — verify anything you intend to rely on.
  • We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
  • Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
  • Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.

Full terms: Disclaimer · Terms of Service · Privacy Policy